See more : New Providence Acquisition Corp. II (NPAB) Income Statement Analysis – Financial Results
Complete financial analysis of XTL Biopharmaceuticals Ltd. (XTLB.TA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of XTL Biopharmaceuticals Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Zilltek Technology Corp. (6679.TWO) Income Statement Analysis – Financial Results
- Bed Bath & Beyond Inc. (BBBY) Income Statement Analysis – Financial Results
- Iris Acquisition Corp (IRAAU) Income Statement Analysis – Financial Results
- Nipro Corporation (8086.T) Income Statement Analysis – Financial Results
- Critical Solutions, Inc. (CSLI) Income Statement Analysis – Financial Results
XTL Biopharmaceuticals Ltd. (XTLB.TA)
About XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.37M | 938.00K | 0.00 | 0.00 | 0.00 | 5.94M | 907.00K | 454.00K | 3.20M | 3.45M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.00 | 741.00K | 380.00K | 0.00 | 0.00 | 0.00 | 0.00 | 110.00K | 54.00K | 2.80M | 3.30M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -17.00 | 1.63M | 558.00K | 0.00 | 0.00 | 0.00 | 5.94M | 797.00K | 400.00K | 400.00K | 153.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 68.72% | 59.49% | 0.00% | 0.00% | 0.00% | 100.00% | 87.87% | 88.11% | 12.51% | 4.43% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.00K | 30.00K | 30.00K | 38.00K | 35.00K | 38.00K | 43.00K | 443.00K | 578.00K | 278.00K | 113.00K | 99.00K | 158.00K | 64.00K | 0.00 | 10.39M | 20.95M | 10.87M | 7.54M | 12.80M | 11.10M | 13.16M | 11.05M |
| General & Administrative | 734.00K | 850.00K | 1.00M | 910.00K | 807.00K | 755.00K | 1.19M | 1.26M | 1.41M | 1.72M | 1.98M | 2.70M | 0.00 | 1.22M | 2.43M | 5.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.69M | 848.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 734.00K | 850.00K | 1.00M | 910.00K | 807.00K | 755.00K | 1.19M | 1.26M | 1.41M | 1.72M | 3.67M | 3.55M | 1.00M | 1.22M | 2.43M | 5.14M | 5.58M | 5.58M | 5.46M | 4.13M | 3.11M | 3.64M | 3.00M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 765.00K | 880.00K | 1.03M | 948.00K | 842.00K | 793.00K | 1.25M | 1.71M | 2.00M | 2.02M | 3.85M | 3.70M | 1.16M | 1.26M | 2.29M | 15.53M | 26.53M | 16.45M | 13.00M | 16.93M | -14.56M | 17.71M | 15.12M |
| Cost & Expenses | 765.00K | 880.00K | 1.03M | 948.00K | 842.00K | 793.00K | 1.25M | 1.71M | 2.00M | 2.02M | 4.59M | 4.08M | 1.16M | 1.26M | 2.29M | 15.53M | 26.64M | 16.50M | 15.79M | 20.23M | -14.56M | 17.71M | 15.12M |
| Interest Income | 36.00 | 36.00K | 8.00K | 33.00K | 93.00K | 87.00K | 16.00K | 0.00 | 0.00 | 10.00K | 10.00K | 43.00K | 45.00K | 2.00K | 3.00K | 317.00K | 668.00K | 1.06M | 503.00K | 352.00K | 352.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 29.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 35.00K | 15.00K | 8.00K | 0.00 | 2.00K | 3.00K | 4.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.00K | 1.00K | 1.00K | 1.00K | 842.00K | 1.00K | 1.00K | 3.00K | 7.00K | 53.00K | 313.00K | 136.00K | 94.00K | 42.00K | 13.00K | 39.00K | 108.00K | 243.00K | 242.00K | 319.00K | 440.00K | 0.00 | 0.00 |
| EBITDA | -764.00K | -879.00K | -1.03M | -947.00K | 0.00 | -792.00K | -1.25M | -1.71M | -2.00M | -1.97M | -1.10M | -3.80M | -1.06M | -1.21M | 2.58M | -18.40M | -25.63M | -15.80M | -12.36M | -16.46M | 15.36M | -17.71M | -15.12M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -8.02% | -404.69% | 0.00% | 0.00% | 0.00% | -155.47% | -2,817.31% | -3,499.12% | -328.81% | -476.46% | 0.00% | 0.00% | 0.00% |
| Operating Income | -765.00K | -880.00K | -1.03M | -948.00K | -842.00K | -793.00K | -1.25M | -2.56M | -3.61M | -2.02M | -2.89M | -2.36M | -1.16M | -1.26M | 2.57M | -9.59M | -25.74M | -16.05M | -14.38M | -16.78M | 14.56M | -17.71M | -15.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -122.16% | -251.17% | 0.00% | 0.00% | 0.00% | -161.46% | -2,837.38% | -3,534.36% | -449.80% | -485.70% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.02M | -468.00K | 1.47M | -2.01M | 79.00K | 4.42M | 465.00K | 16.00K | -11.00K | -97.00K | -3.36M | 614.00K | -44.00K | -1.00K | -4.00K | -8.87M | 590.00K | 1.14M | 443.00K | 352.00K | -28.77M | 597.00K | 0.00 |
| Income Before Tax | -1.78M | -1.35M | 435.00K | -782.00K | -1.35M | 2.99M | -781.00K | -2.55M | -3.62M | -2.12M | -3.71M | -1.74M | -1.21M | -1.26M | 2.56M | -9.28M | -25.15M | -14.91M | -13.94M | -16.42M | -14.21M | -17.11M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -156.73% | -185.71% | 0.00% | 0.00% | 0.00% | -156.18% | -2,772.33% | -3,283.04% | -435.94% | -475.51% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 468.00K | -1.47M | -166.00K | -69.00K | -80.00K | -457.00K | 832.00K | 2.31M | 505.00K | 458.00K | -1.19M | 6.00K | 0.00 | -23.00K | -31.00K | -206.00K | 227.00K | 78.00K | 49.00K | 78.00K | 27.00K | 12.67M |
| Net Income | -1.78K | -1.35M | 435.00K | -782.00K | -1.35M | 2.99M | -781.00K | -2.55M | -4.31M | -2.53M | -2.48M | -1.39M | -1.21M | -1.26M | 2.59M | -9.25M | -24.94M | -15.13M | -14.02M | -16.47M | -14.29M | -17.14M | -12.67M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -104.52% | -148.19% | 0.00% | 0.00% | 0.00% | -155.66% | -2,749.61% | -3,333.04% | -438.38% | -476.93% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | 0.04 | -0.16 | -0.55 | -0.38 | -0.41 | -0.61 | -0.64 | -0.77 | -0.57 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | 0.04 | -0.16 | -0.55 | -0.38 | -0.04 | -0.06 | -0.64 | -0.77 | -0.57 |
| Weighted Avg Shares Out | 544.95M | 544.91M | 615.55M | 514.21M | 514.21M | 514.21M | 470.19M | 274.04M | 263.73M | 231.22M | 223.61M | 217.69M | 204.03M | 113.40M | 58.56M | 58.55M | 45.70M | 40.35M | 34.02M | 26.95M | 22.34M | 22.23M | 22.19M |
| Weighted Avg Shares Out (Dil) | 544.91M | 544.91M | 615.55M | 514.21M | 514.21M | 514.21M | 470.19M | 274.04M | 263.73M | 231.22M | 223.61M | 217.69M | 204.03M | 113.40M | 58.77M | 58.55M | 45.70M | 40.35M | 337.08M | 274.53M | 22.34M | 22.23M | 22.19M |
Source: https://incomestatements.info
Category: Stock Reports